Calliditas

Liver
Biotech

Calliditas' rethought liver disease trial hits primary endpoint

The biotecch only saw a positive trend on liver stiffness and reported a higher rate of dropouts on the drug.
Nick Paul Taylor Jul 26, 2024 5:32am
success failure signposts

Calliditas' cancer trial misses primary goal, hits on survival

May 7, 2024 6:39am
race track

Alnylam closes in on phase 3 launch for Regeneron-partnered med

Aug 29, 2022 12:46pm
Patients undergoing kidney dialysis must have their hydration level closely monitored a newly-developed portable sensor make

Alnylam stays on Calliditas' heels, passing a phase 2 checkpoint

Jun 9, 2022 10:21am